KR880011197A - 위장장해를 치료하기 위한 조성물 및 방법 - Google Patents

위장장해를 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR880011197A
KR880011197A KR1019880002556A KR880002556A KR880011197A KR 880011197 A KR880011197 A KR 880011197A KR 1019880002556 A KR1019880002556 A KR 1019880002556A KR 880002556 A KR880002556 A KR 880002556A KR 880011197 A KR880011197 A KR 880011197A
Authority
KR
South Korea
Prior art keywords
campylobacter
secretion inhibitor
inhibiting
receptor
secretion
Prior art date
Application number
KR1019880002556A
Other languages
English (en)
Other versions
KR970007188B1 (ko
Inventor
플레이스 제프리
Original Assignee
원본 미기재
더 프록터 앤드 갬블 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21816098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR880011197(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본 미기재, 더 프록터 앤드 갬블 캄파니 filed Critical 원본 미기재
Publication of KR880011197A publication Critical patent/KR880011197A/ko
Application granted granted Critical
Publication of KR970007188B1 publication Critical patent/KR970007188B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용없음

Description

위장장해를 치료하기 위한 조성물 및 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (21)

  1. 캄피로박터-억제 살균제 ; H2수용기 차단-분비억제제 ; 및 약제학적으로 허용되는 담체로 이루어짐을 특징으로 하는, 위장장해를 치료 또는 예방하기 위한 약제학적 조성물.
  2. 제1항에 있어서, 캄피로박터-억제 살균제가 살균성 니트로푸란 및 항생제로 이루어진 그룹중에서 선택되는 조성물.
  3. 제1항에 또는 제2항에 있어서, 캄필로박터-억제 살균제가 니트로푸란토인인 조성물.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, H2수용기 차단-분비 억제제가 시메티딘, 라니티딘 및 이들의 혼합물로 이루어진 그룹중에서 선택되는 조성물.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, H2수용기 차단-분비 억제제가 시메티딘인 조성물.
  6. 인체 또는 하등 동물에게 1일 1mg 내지 10g의 양으로 캄필로박터-억제 살균제를 투여하고 안전유효량의 H2수용기 차단-분비 억제제를 투여하여 인체 또는 하등 동물의 위장장해를 치료 또는 예방하는 약제를 제조하기 위한 캄필로박터-억제 살균제의 용도.
  7. 제6항에 있어서, 캄필로박터-억제 살균제 및 H2수용지 차단-분비 억제제를 동시에 투여하여 치료 또는 에방하기 위한 캄필로박터-억제 살균제의 용도.
  8. 제6항에 있어서, 캄필로박터-억제 살균제 및 H2수용기 차단-분비 억제제를 간격을 두고 투여하여 치료 또는 예방하기 위한 캄필로박터-억제 살균제의 용도.
  9. 제6항 내지 제8항 중의 어느 한 항에 있어서, 캄필로박터-억제 살균제는 살균성 니트로푸란 및 항생제로 이루어진 그룹으로부터 선택되며, H2수용기 차단-분비 억제제는 시메티딘, 리니티딘 및 이들의 혼합물로 이루어진 그룹으로부터 선택되며, H2수용기 차단-분비 억제제는 시메티딘, 라니티딘 및 이들의 혼합물로 이루어진 그룹으로부터 선택되는 캄필로박터-억제 살균제의 용도.
  10. 제6항 내지 제9항 중 어느 한 항에 있어서, 캄필로박터-억제 살균제가 니트로푸란티온인 캄필로박터-억제 살균제의 용도.
  11. 제6항 내지 제10항 중 어느 한 항에 있어서, 위장장해가 비궤양성 위장장해인 캄필로박터-억제 살균제의 용도.
  12. 제6항 내지 제10항 중 어느 한 항에 있어서, 위장장해가 소화성 궤양증인 캄필로박터-억제 살균제의 용도.
  13. 인체 또는 하등 동물에게 1일 1mg 내지 10g의 양으로 H2수용기 차단-분비 억제제를 투여하고 안전유효량의 캄피로박터-억제 살균제를 투여하여 인체 또는 하등 동물의 위장장해를 치료 또는 예방하는 약제를 제조하기 위한 H2수용기 차단 분비 억제제의 용도.
  14. 제13항에 있어서, 캄필로박터-억제제 및 H2수용기 차단-분비 억제제를 동시에 투여하여 치료 또는 예방하기 위한 H2수용기 차단-분비 억제제의 용도.
  15. 제13항 있어서, 캄필로박터-억제제 및 H2수용기 차단-분비 억제제를 간격을 두고 투여하여 치료 또는 예방하기 위한 H2수용기 차단-분비 억제제의 용도.
  16. 제13항 내지 제15항 중 어느 한 항에 있어서, 캄필로박터-억제 살균제가 살균성 니트로푸란 및 항생제로 이루어진 그룹으로부터 선택되며, H2수용기차단-분비 억제제가 시메티딘, 라니티딘 및 이들의 혼합물로 이루어진 그룹으로부터 선택되는 H2수용기 차단-분비 억제제의 용도.
  17. 제13항 내지 제16항 중 어느 한 항에 있어서, 캄필로박터-억제 살균제가 니트로푸란토인인 H2수용기 차단-분비 억제제의 용도.
  18. 제13항 내지 제17항 중 어느 한 항에 있어서, H2수용기 차단-분비 억제제가 시메티딘인 H2수용기 차단-분비 억제제의 용도.
  19. 제13항 내지 제17항 중 어느 한 항에 있어서, H2수용기 차단-분비 억제제가 라니티딘인 H2수용기 차단-분비 억제제의 용도.
  20. 제13항 내지 제19항 중 어느 한 항에 있어서, 위장장해가 비궤양성 위장장해인 H2수용기 차단-분비 억제제의 용도.
  21. 제13항 내지 제19항 중 어느 한 항에 있어서, 위장장해가 소화성 궤양증인 H2수용기 차단-분비 억제제이 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880002556A 1987-03-09 1988-03-09 위장장해 치료 조성물 KR970007188B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2359687A 1987-03-09 1987-03-09
US23596 1987-03-09
US023,596 1987-03-09

Publications (2)

Publication Number Publication Date
KR880011197A true KR880011197A (ko) 1988-10-27
KR970007188B1 KR970007188B1 (ko) 1997-05-07

Family

ID=21816098

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880002556A KR970007188B1 (ko) 1987-03-09 1988-03-09 위장장해 치료 조성물

Country Status (13)

Country Link
US (1) US5407688A (ko)
EP (2) EP0578965A1 (ko)
JP (1) JP2648328B2 (ko)
KR (1) KR970007188B1 (ko)
AT (1) ATE117206T1 (ko)
AU (2) AU621285B2 (ko)
CA (1) CA1312012C (ko)
DE (1) DE3852773T2 (ko)
DK (1) DK175866B1 (ko)
IE (2) IE66367B1 (ko)
IL (1) IL85472A (ko)
NZ (1) NZ223774A (ko)
ZA (1) ZA881678B (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
CH679582A5 (ko) * 1988-07-18 1992-03-13 Glaxo Group Ltd
AU641903B2 (en) * 1988-10-26 1993-10-07 Glaxo Group Limited Carboxylic acid derivatives
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
US5843482A (en) * 1990-07-20 1998-12-01 Tillotts Pharma Ag Products and processes for the treatment of the alimentary canal
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
ATE209914T1 (de) * 1990-09-14 2001-12-15 Byk Gulden Lomberg Chem Fab Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
US5192752A (en) * 1991-01-14 1993-03-09 The Procter & Gamble Company Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
ES2130152T3 (es) * 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
IL105155A (en) * 1992-04-24 1999-05-09 Astra Ab Synergistic combination of an inhibitor of gastric acid secretion with an acid-breaking antibiotic
EP0703782A1 (en) * 1993-06-15 1996-04-03 Pfizer Inc. H2-antagonists as immune stimulants in bacterial infections of cattle or swine
WO1996014068A1 (de) * 1994-11-07 1996-05-17 Asche Ag Arzneimittel zur behandlung von erkrankungen des magen-darm-traktes
US5861518A (en) * 1994-11-21 1999-01-19 Dekker; Koenraad A. Phthalide compounds and their production process
JP3767831B2 (ja) * 1995-06-14 2006-04-19 木村 健 ヘリコバクター・ピロリ除菌用組成物
AU1117497A (en) * 1995-11-13 1997-06-05 Albany Medical College Analgesic compounds and uses thereof
US5744168A (en) * 1995-12-07 1998-04-28 The Procter & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
CA2349575A1 (en) * 1998-11-17 2000-05-25 Nitromed, Inc. Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
ES2376466T3 (es) 2004-05-07 2012-03-14 Nycomed Gmbh Forma de dosificación farmacéutica que comprende peletes, as�? como su procedimiento de fabricación.
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
JP2011178722A (ja) * 2010-03-01 2011-09-15 Synmosa Biopharma Corp ヘリコバクタ−・ピロリ（Ｈ．ｐｙｌｏｒｉ）を除菌する医薬組成物及びその製造方法
EP2601947A1 (en) * 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2218883B1 (ko) * 1973-02-28 1976-08-13 Science Union & Cie
US4333922A (en) * 1974-09-12 1982-06-08 Herschler R J Method for the treatment of water-living animals with health modifying agents
CH638975A5 (fr) * 1979-07-27 1983-10-31 Prebuilt Ets Composition medicamenteuse pour le traitement des ulceres gastro-duodenaux.
EP0222834A4 (en) * 1985-04-18 1989-10-04 Borody Thomas J TREATMENT OF NON-ULCERATIVE DYSPEPSIA WITH BISMUTOUS SALTS.
EP0206627B1 (en) * 1985-06-13 1992-08-12 Barry James Dr. Marshall Methods for the treatment of gastrointestinal disorders
ATE135582T1 (de) * 1985-06-13 1996-04-15 Barry James Marshall Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen
US4959384A (en) * 1985-10-24 1990-09-25 Norwich Eaton Pharmaceuticals, Inc. Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
CH679582A5 (ko) * 1988-07-18 1992-03-13 Glaxo Group Ltd
DE3830616A1 (de) * 1988-09-09 1990-03-15 Ruetgerswerke Ag Prophylaktikum fuer fische

Also Published As

Publication number Publication date
EP0282131A3 (en) 1989-11-15
US5407688A (en) 1995-04-18
JPS63290831A (ja) 1988-11-28
EP0578965A1 (en) 1994-01-19
DE3852773T2 (de) 1995-07-06
KR970007188B1 (ko) 1997-05-07
IE880665L (en) 1988-09-09
DK175866B1 (da) 2005-04-18
CA1312012C (en) 1992-12-29
NZ223774A (en) 1991-02-26
AU660645B2 (en) 1995-07-06
DK127788D0 (da) 1988-03-09
ZA881678B (en) 1988-09-07
JP2648328B2 (ja) 1997-08-27
EP0282131B1 (en) 1995-01-18
AU1279388A (en) 1988-09-08
ATE117206T1 (de) 1995-02-15
EP0282131A2 (en) 1988-09-14
IL85472A (en) 1991-06-30
AU621285B2 (en) 1992-03-12
IE950632L (en) 1988-09-09
DK127788A (da) 1988-09-10
AU1030292A (en) 1992-03-05
IE66367B1 (en) 1995-12-27
DE3852773D1 (de) 1995-03-02

Similar Documents

Publication Publication Date Title
KR880011197A (ko) 위장장해를 치료하기 위한 조성물 및 방법
KR880010768A (ko) 위장장해의 치료 및 예방용 약제학적 조성물
FI941771A0 (fi) Tehostettu ihonläpäisyjärjestelmä lääkeaineiden parannettua paikallista antoa varten
KR920002144A (ko) 아연 l-카르노신 염 또는 이의 착화합물을 유효성분으로 함유하는 염증성 장질환 예방 및 치료제
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
DE69328186T2 (de) Zusammensetzung zur behandlung der parkinson-krankheit
KR910009273A (ko) 위장관계 통증 치료용 약제학적 조성물
ATE165514T1 (de) Verwendung von inosittriphosphat zur zubereitung von medikamenten
RU99107569A (ru) Фармацевтические композиции, обладающие антимикробной активностью
NO923199D0 (no) Terapeutiske forbindelser
DE69927584D1 (de) Pharmazeutische zubereitungen zur behandlung von magengeschwüren
FI923662A0 (fi) Terapeutiska medel.
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
KR880009656A (ko) 국소 치근막 질환의 치료 또는 예방법
ATE88634T1 (de) Arzneimittel zur behandlung von herzinsuffizienz.
EP0505389A4 (en) Antiparasitic composition for animal use
GEP20032956B (en) Miticide Composition
KR890001543A (ko) 당뇨병 치료제
SE9304065D0 (sv) New compound
RU94019942A (ru) Фармацевтическая композиция для повышения проницаемости кожи для улучшенной локальной доставки лекарств
RU94019328A (ru) α- ГЕТЕРОАРИЛОКСИМЕТИЛКЕТОНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ИНГИБИРУЮЩАЯ ИНТЕРЛЕЙКИН-1 - β -ПРОТЕАЗУ
JO1519B1 (en) New compounds (new benzimidazole derivatives are effective as ulcers)
NO950842L (no) Diarylpiperazinoacetamidforbindelser som antimuskariniske midler

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110818

Year of fee payment: 15

EXPY Expiration of term